NewAmsterdam Pharma N.V. (NAMS) vs Perrigo (PRGO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Perrigo (PRGO) has outperformed NewAmsterdam Pharma N.V. (NAMS) over the past year, gaining 26.1% versus a loss of 51.9%. Over five years, NAMS leads with a +88.0% price change compared with -57.8% for PRGO. Perrigo is the larger company by market cap ($2.21 billion vs $2.21 billion), about 1.0 times the size.
Perrigo pays a dividend yielding 7.28%, while NewAmsterdam Pharma N.V. does not currently pay one. Perrigo converts more of its revenue into profit, with a net margin of -33.5% versus -905.7%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NAMS | PRGO |
|---|---|---|
| Share price | $18.41 | $15.94 |
| Market cap | $2.21B | $2.21B |
| 1-day change | -5.64% | -0.62% |
| YTD return | -47.52% | +14.51% |
| 1-year return | -51.89% | +26.11% |
| 5-year return | +88.05% | -57.81% |
| Forward P/E | — | 6.94 |
| EPS (TTM) | $-1.69 | $-12.47 |
| Dividend yield | 0.00% | 7.28% |
| Annual dividend | $0.00 | $1.16 |
| Revenue (latest FY) | $22.50M | $4.25B |
| Revenue growth (YoY) | -50.61% | -2.75% |
| Net income (latest FY) | $-203.82M | $-1.43B |
| Gross margin | — | 35.14% |
| Operating margin | -1002.90% | -26.39% |
| Net margin | -905.74% | -33.51% |
| 52-week high | $42.21 | $17.07 |
| 52-week low | $17.90 | $9.23 |
| Distance from 52-week high | -56.38% | -6.62% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +174.85% | +12.92% |
| Average volume | 1.66M | 2.54M |
| Shares outstanding | 119.93M | 138.80M |
| Employees | 100 | 8,100 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PRGO has outperformed NAMS by 78.0 percentage points over the past year.
- Perrigo offers a meaningfully higher dividend yield (7.28% vs 0.00%).
- Perrigo is more profitable, keeping -33.5 cents of every revenue dollar as net income versus -905.7 cents for NewAmsterdam Pharma N.V..
- Perrigo grew revenue faster in its latest fiscal year (-2.75% vs -50.61%).
About NewAmsterdam Pharma N.V.
NAMS stock →NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 100 employees
About Perrigo
PRGO stock →Perrigo Company plc provides over-the-counter health and wellness solutions in the United States, Europe, and internationally. The company operates through Consumer Self-Care Americas and Consumer Self-Care International segments.
Health Care · Biotechnology: Pharmaceutical Preparations · 8,100 employees
NAMS vs PRGO FAQ
Which is bigger, NewAmsterdam Pharma N.V. or Perrigo?
Perrigo (PRGO) is larger, with a market capitalization of $2.21B compared with $2.21B for NewAmsterdam Pharma N.V. (NAMS).
Which stock has performed better over the past year, NAMS or PRGO?
PRGO returned +26.11% over the past 12 months, compared with -51.89% for NAMS (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, NewAmsterdam Pharma N.V. or Perrigo?
Perrigo pays a dividend yielding 7.28%, while NewAmsterdam Pharma N.V. does not currently pay a regular dividend.
Are NewAmsterdam Pharma N.V. and Perrigo in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.